Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;17(4):1170-1178.
doi: 10.1055/s-0042-1760301. Epub 2023 Jan 30.

Prediction of Lymphovascular and Perineural Invasion of Oral Squamous Cell Carcinoma by Combined Expression of p63 and Cyclin D1

Natheer H Al-Rawi  1 , Sausan Al Kawas  1 , Muwaffaq Al Ani  2 , Ahmed Sameer Alnuaimi  3 , Walid El-Sayed  4   5 , Mohammad S Alrashdan  1   6
Affiliations

Prediction of Lymphovascular and Perineural Invasion of Oral Squamous Cell Carcinoma by Combined Expression of p63 and Cyclin D1

Natheer H Al-Rawi et al. Eur J Dent. 2023 Oct.

Abstract

Objectives: The aim of this study was to determine the value of immune expression of p63 and cyclin D1 in the prediction of lymphovascular invasion (LVI) and perineural invasion (PNI) in oral squamous cell carcinoma (OSCC).

Materials and methods: Clinical and histopathologic features of 65 subjects with histologically confirmed OSCC were collected. Tissue microarray blocks representing all subjects were prepared for the immunohistochemical quantification of the nuclear expression of p63 and cyclin D1 using immune ratio plugin of image J software. Image analysis was performed by two independent pathologists. Independent samples t-test, analysis of variance, and receiver operating characteristic curve tests were used for statistical analysis. The level of significance was set at p≤ 0.05.

Results: The optimum cutoff value for the prediction of LVI for p63 and cyclin D1 was found to be 100 and 93.2, respectively, while the optimum cutoff value for the prediction of PNI for p63 and cyclin D1 was found to be 95.9 and 94, respectively. p63 and cyclin D1 expression correlated with several clinicopathologic features of the studied population. p63 expression was a significant predictor of moderate/poorly differentiated OSCC compared with well-differentiated OSCC. A parallel combination of positive p63 and cyclin D1 increased the specificity of predicting LVI from 89.1% and 67.4% for either p63 or cyclin D1, respectively, to 93.5% with a positive predictive value of 92.5%. Similarly, the parallel combination of the two markers raised the specificity of predicting PNI from 70% and 77.5% for either p63 or cyclin D1, respectively, to 90% with a positive predictive value of 86.3%.

Conclusion: Combined overexpression of nuclear markers p63 and cyclin D1 can be considered as a valuable independent predictor of LVI and PNI, and hence tumor progression, in OSCC.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Fig. 1
Fig. 1
( A ) Perineural invasion of malignant epithelial cells (magnification X10). ( B ) Vascular invasion by malignant epithelial cells (magnification X40).
Fig. 2
Fig. 2
( A ) Hematoxylin and eosin atain of the selected area. ( B ) Nuclear expression of p63; strong expression of p63 at basal and suprabasal cells of malignant epithelial islands; nuclear expression of cyclin D1; strong expression of basal and suprabasal cells at the invasive front. (magnification x10).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel R L et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(03):209–249. - PubMed
    1. Murthy V, Agarwal J P, Laskar S G et al. Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther. 2010;6(03):282–289. - PubMed
    1. Chinn S B, Myers J N. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol. 2015;33(29):3269–3276. - PMC - PubMed
    1. Hosokawa Y, Arnold A. Cyclin D1/PRAD1 as a central target in oncogenesis. J Lab Clin Med. 1996;127(03):246–252. - PubMed
    1. Todd R, Hinds P W, Munger K et al. Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med. 2002;13(01):51–61. - PubMed